RetinalGenix Technologies Inc. Annual Report: A Simple Breakdown

I’ve put together this guide to help you understand how RetinalGenix Technologies performed this year. My goal is to turn complex financial filings into clear information so you can decide if this company fits your investment goals.

1. What does this company do?

RetinalGenix is an eye-care research company based in Apollo Beach, Florida. They are currently in the development stage, focusing on creating new diagnostic and treatment tools. Their business rests on four main pillars:

• Genetic Testing: Developing an oral swab to identify your risk for retinal diseases.
• Retinal Imaging: Engineering the "RetinalCam," a portable device that lets patients monitor their eye health from home.
• Patient Database: Building a secure, cloud-based system to store patient data for research.
• Pharmaceuticals: Researching new drugs for eye conditions like macular degeneration and potentially Alzheimer’s.

2. Financial Health: The "Burn"

The company is currently in a capital-intensive phase. They have zero revenue from sales and lost about $1.6 million this year due to research and administrative costs.

With less than $100,000 in cash on hand, the company requires approximately $7 million in new funding to support clinical trials and manufacturing. Without this capital, the company faces significant challenges in maintaining operations over the next 12 months.

3. The Roadmap: What’s coming next?

The company’s ability to execute its schedule depends on securing the necessary $7 million in funding:

• Late 2026: Target launch for the genetic swab test.
• 2026/2027: Expected start of the FDA approval process for the "RetinalCam" remote monitoring device.
• 2027: Development of a second genetic test for specific eye diseases.
• Ongoing: Research into new drugs remains a long-term goal, though these projects are currently paused pending further funding.

4. Key Risks: What could go wrong?

Investing in early-stage research companies involves significant risk. Consider these factors before making a decision:

• Survival Risk: The company’s limited cash reserves mean they must raise additional capital to continue operations.
• Dilution: Because the company has no revenue, they rely on selling more shares to fund their work, which reduces the ownership percentage of existing shareholders.
• Regulatory Hurdles: Success is tied to FDA approval. If the company fails to meet regulatory standards, they cannot bring their primary products to market.
• Penny Stock Status: The stock trades at a low price, which can lead to high volatility and lower liquidity, making it harder to buy or sell shares.
• No Dividends: The company is not profitable and does not pay dividends.

5. Competitive Positioning

RetinalGenix aims to shift eye care from the doctor’s office to the home by combining their "RetinalCam" hardware with a proprietary genetic database. They operate in a space with established competitors who possess significantly larger budgets. Their long-term viability depends on successfully patenting their technology, passing government testing, and proving that their tools offer a clear advantage over current medical standards.

Final Thought for Investors: This is a high-risk, speculative opportunity. Because the company is not yet generating revenue and has very little cash, your investment is essentially a bet on their ability to raise millions of dollars and successfully navigate the FDA approval process. If you are considering this stock, ensure it represents only a small, experimental portion of your portfolio that you are comfortable potentially losing.